World Health Organization : Year 1998 ; World Health Organization, Human Genetics Programme Fh Cons, No. 98.7: Familiat, Hypercholesterolaemia 0 Report of a World Health Organization Consultation

By World Health Organization

Book Id: WPLBN0000104638
Format Type: PDF eBook
File Size: 2.6 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 1998 ; World Health Organization, Human Genetics Programme Fh Cons, No. 98.7: Familiat, Hypercholesterolaemia 0 Report of a World Health Organization Consultation
Author:	World Health Organization
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Organization, W. H. (n.d.). World Health Organization : Year 1998 ; World Health Organization, Human Genetics Programme Fh Cons, No. 98.7. Retrieved from http://www.self.gutenberg.org/

Description
Medical Reference Publication

Excerpt
1. INTRODUCTION Primary hypercholesterolaemia (i.e., elevation of plasma low density lipoprotein-cholesterol (LDLcholesterol) which is not secondary to environmental, dietary, or other underlying diseases) is a relatively common condition that has been associated with the development of atherosclerosis and premature cardiovascular disease. More than half of all deaths in Western society are related to atherosclerotic cardiovascular diseases [I]. The pathogenesis of atherosclerosis results from a combination of heritable and environmental factors. Inherited disturbances in the low - density-lipoprotein (LDL) receptor and similar lipid-related defects account for the majority of these deaths [2]. Three recent studies indicate that heart attacks can be reduced by one third, and deaths related to heart attacks by nearly 40%, with drug treatment in high-risk individuals [3-51. The definition of high risk is important, because serum cholesterol levels included in this category overlap the normal range.

Table of Contents
Contents Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . , . . . . . . .2 Molecular Basis of FH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 DNA Diagnosis of FH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 Clinical Criteria for the Diagnosis of FH . . . . . . . . . . . . . . . . . . . . . . . . . . . .6 Treatment of FH Adults with Medication . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 LDL-apheresis for FH Homozygotes and Unresponsive Reterozygotes . . . . . . . . . 14 Role of Diet and Treating Children with FH . . . . . . . . . . . . . . . . . . . . . . . . . 14 Psychosocial Aspects of FR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Approaches for Cardiologists seeing FH Adults . . . . . . . . . . . . . . . . . . . . . . . 19 Long Term Family Physician Approach to FH . . . . . . . . . . . . . . . . . . . . . . . . 21 Contacting and Helping Relatives with FH . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Government Cooperation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27 Cost Effectiveness of Diagnosing and Treating FH . . . . . . . . . . . . . . . . . . . . . 31 MedPed Paradigm for Other Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Conclusions and Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 List of Participants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39